# Sophonix Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sophonix-co

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.sophonix.net
- Total disclosed funding: $30M
- Latest round: Series B (Sep 22, 2021)
- Investors on record: 11

## About

Established in 2017 and based in Beijing, China, Sophonix Co., Ltd. is a healthcare company that focuses on the research and development of in vitro diagnostic equipment and reagents. At present, the company has more than 200 employees and has more than 200 employees and has established 6,000 square meters and 9,300 square meters of in vitro diagnostic equipment and reagent production bases in Beijing and Nanchang respectively. The core team has more than 15 years of experience in the IVD field. In March 2021, the company launched an accurate and rapid traumatic brain injury blood detection system.

The company's self-developed products include automatic chemiluminescence immunoassay analyzers (CLEIA method), pathological diagnosis system (Automatic Immunohistochemical Staining Machine), molecular diagnosis system (Isothermal Nucleic Acid Amplification Analyzer, LAMP technology) and a broad panel of compatible tests, which are suitable for POCT rapid detection. Besides, the company has self-developed immunodiagnostic detection reagent products used in the field of brain diseases, bone metabolism, cardiovascular and cerebrovascular, inflammation detection, gastric function, thyroid function, diabetes, thrombosis, hypertension, gonads ,and hormones.

The company's plan is to use the series B+ funding for the research and development of traumatic brain injury blood detection system and MS-FAST Pro series chemiluminescence POCT products.

## Funding rounds

- Series B, Sep 22, 2021, $15M — Huajin Lingchuang Fund Management, Daokang Zhihe, CITIC Med Fund
- Series B, Jun 23, 2020, $14M — Zero2IPO Ventures, Delian Capital, AnlongMed Investment, GoldTech Capital, Daokang Zhihe, Mingshi Investment Management
- Series A, Feb 25, 2019 — Jiadaogu Capital
- Angel, Dec 21, 2017 — Jiahao Investment, Beijing Zhihe Kangdao Biotechnology

## Investors

- Jiahao Investment (https://capitalatlas.ai/funds/jiahao-investment) — Angel
- Beijing Zhihe Kangdao Biotechnology — Angel
- Jiadaogu Capital (https://capitalatlas.ai/funds/jiadaogu-capital) — Series A
- Zero2IPO Ventures (https://capitalatlas.ai/funds/zero2ipo-ventures) — Series B
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series B
- AnlongMed Investment — Series B
- GoldTech Capital (https://capitalatlas.ai/funds/goldtech-capital) — Series B
- Daokang Zhihe — Series B
- Mingshi Investment Management (https://capitalatlas.ai/funds/mingshi-investment-management) — Series B
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series B
- CITIC Med Fund (https://capitalatlas.ai/funds/citic-med-fund) — Series B